Heterocyclic aspartyl protease inhibitors
US8183252B2 · kind B2 · utility
8Cited by
66References
88Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 26, 2010 |
| Grant date | May 22, 2012 |
| Priority date | — |
| Expiry date | May 10, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/4178
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are compounds of the formula Ior a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.